BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24242937)

  • 21. Differential interactions of the β-lactam cloxacillin with human renal organic anion transporters (OATs).
    Lalanne S; Le Vée M; Lemaitre F; Le Corre P; Verdier MC; Fardel O
    Fundam Clin Pharmacol; 2020 Aug; 34(4):476-483. PubMed ID: 32100322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benzylpenicillin inhibits the renal excretion of acyclovir by OAT1 and OAT3.
    Ye J; Liu Q; Wang C; Meng Q; Sun H; Peng J; Ma X; Liu K
    Pharmacol Rep; 2013; 65(2):505-12. PubMed ID: 23744435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bezafibrate-mizoribine interaction: Involvement of organic anion transporters OAT1 and OAT3 in rats.
    Feng Y; Wang C; Liu Q; Meng Q; Huo X; Liu Z; Sun P; Yang X; Sun H; Qin J; Liu K
    Eur J Pharm Sci; 2016 Jan; 81():119-28. PubMed ID: 26474691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cetuximab Prevents Methotrexate-Induced Cytotoxicity in Vitro through Epidermal Growth Factor Dependent Regulation of Renal Drug Transporters.
    Caetano-Pinto P; Jamalpoor A; Ham J; Goumenou A; Mommersteeg M; Pijnenburg D; Ruijtenbeek R; Sanchez-Romero N; van Zelst B; Heil SG; Jansen J; Wilmer MJ; van Herpen CML; Masereeuw R
    Mol Pharm; 2017 Jun; 14(6):2147-2157. PubMed ID: 28493713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction of human organic anion transporters with various cephalosporin antibiotics.
    Takeda M; Babu E; Narikawa S; Endou H
    Eur J Pharmacol; 2002 Mar; 438(3):137-42. PubMed ID: 11909604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Organic anion transporters involved in the excretion of bestatin in the kidney.
    Zhu Y; Meng Q; Wang C; Liu Q; Sun H; Kaku T; Liu K
    Peptides; 2012 Feb; 33(2):265-71. PubMed ID: 22273603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics.
    Vallon V; Rieg T; Ahn SY; Wu W; Eraly SA; Nigam SK
    Am J Physiol Renal Physiol; 2008 Apr; 294(4):F867-73. PubMed ID: 18216144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Roles of organic anion transporters in the renal excretion of perfluorooctanoic acid.
    Nakagawa H; Hirata T; Terada T; Jutabha P; Miura D; Harada KH; Inoue K; Anzai N; Endou H; Inui K; Kanai Y; Koizumi A
    Basic Clin Pharmacol Toxicol; 2008 Jul; 103(1):1-8. PubMed ID: 18373647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interactions between Oroxylin A with the solute carrier transporters and ATP-binding cassette transporters: Drug transporters profile for this flavonoid.
    Ren G; Qin Z; Yang N; Chen H; Fu K; Lu C; Lu Y; Li N; Zhang Y; Chen X; Zhao D
    Chem Biol Interact; 2020 Jun; 324():109097. PubMed ID: 32305507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aspirin and probenecid inhibit organic anion transporter 3-mediated renal uptake of cilostazol and probenecid induces metabolism of cilostazol in the rat.
    Wang C; Wang C; Liu Q; Meng Q; Cang J; Sun H; Peng J; Ma X; Huo X; Liu K
    Drug Metab Dispos; 2014 Jun; 42(6):996-1007. PubMed ID: 24692216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of JBP485 on obstructive jaundice is related to regulation of renal Oat1, Oat3 and Mrp2 expression in ANIT-treated rats.
    Liu T; Guo X; Meng Q; Wang C; Liu Q; Sun H; Ma X; Kaku T; Liu K
    Peptides; 2012 Jul; 36(1):78-85. PubMed ID: 22521734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of drug-drug interaction between the novel cPLA2 inhibitor AK106-001616 and methotrexate in rheumatoid arthritis patients.
    Kozaki T; Tagashira M; Yamanishi K; Ellis B; Kayanoki T; Ooishi R; Sugiyama K; Matsuda S; Tsuruta K; Kohira T; Tsurui K
    Xenobiotica; 2015; 45(7):615-24. PubMed ID: 25579091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JBP485 improves gentamicin-induced acute renal failure by regulating the expression and function of Oat1 and Oat3 in rats.
    Guo X; Meng Q; Liu Q; Wang C; Sun H; Peng J; Ma X; Kaku T; Liu K
    Toxicol Appl Pharmacol; 2013 Sep; 271(2):285-95. PubMed ID: 23707770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Caffeic acid inhibits organic anion transporters OAT1 and OAT3 in rat kidney.
    Uwai Y; Kawasaki T; Nabekura T
    Drug Metabol Drug Interact; 2013; 28(4):247-50. PubMed ID: 24166669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate.
    Elsby R; Fox L; Stresser D; Layton M; Butters C; Sharma P; Smith V; Surry D
    Eur J Pharm Sci; 2011 May; 43(1-2):41-9. PubMed ID: 21440623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3.
    Narumi K; Sato Y; Kobayashi M; Furugen A; Kasashi K; Yamada T; Teshima T; Iseki K
    Biopharm Drug Dispos; 2017 Dec; 38(9):501-508. PubMed ID: 28801980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of 1α,25-dihydroxyvitamin D3 , the natural vitamin D receptor ligand, on the pharmacokinetics of cefdinir and cefadroxil, organic anion transporter substrates, in rat.
    Kim YC; Kim IB; Noh CK; Quach HP; Yoon IS; Chow ECY; Kim M; Jin HE; Cho KH; Chung SJ; Pang KS; Maeng HJ
    J Pharm Sci; 2014 Nov; 103(11):3793-3805. PubMed ID: 25266751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. From the Cover: Identification of Natural Products as Inhibitors of Human Organic Anion Transporters (OAT1 and OAT3) and Their Protective Effect on Mercury-Induced Toxicity.
    Wang X; Han L; Li G; Peng W; Gao X; Klaassen CD; Fan G; Zhang Y
    Toxicol Sci; 2018 Feb; 161(2):321-334. PubMed ID: 29045746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A role for the organic anion transporter OAT3 in renal creatinine secretion in mice.
    Vallon V; Eraly SA; Rao SR; Gerasimova M; Rose M; Nagle M; Anzai N; Smith T; Sharma K; Nigam SK; Rieg T
    Am J Physiol Renal Physiol; 2012 May; 302(10):F1293-9. PubMed ID: 22338083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.
    Rizk ML; Houle R; Chan GH; Hafey M; Rhee EG; Chu X
    Antimicrob Agents Chemother; 2014; 58(3):1294-301. PubMed ID: 24295974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.